Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EVG NASDAQ:ONC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVGEaton Vance Short Duration Diversified Income Fund$10.79+1.1%$10.75$10.40▼$11.45N/AN/A38,581 shs36,353 shsONCBeOne Medicines$270.15+2.8%$296.16$239.25▼$385.22$28.82B0.49270,918 shs367,884 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVGEaton Vance Short Duration Diversified Income Fund+1.17%+0.56%+2.02%+3.16%-0.32%ONCBeOne Medicines+2.84%+3.80%-9.04%-1.86%+6.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVGEaton Vance Short Duration Diversified Income Fund$10.79+1.1%$10.75$10.40▼$11.45N/AN/A38,581 shs36,353 shsONCBeOne Medicines$270.15+2.8%$296.16$239.25▼$385.22$28.82B0.49270,918 shs367,884 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVGEaton Vance Short Duration Diversified Income Fund+1.17%+0.56%+2.02%+3.16%-0.32%ONCBeOne Medicines+2.84%+3.80%-9.04%-1.86%+6.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVGEaton Vance Short Duration Diversified Income Fund 0.00N/AN/AN/AONCBeOne Medicines 2.93Moderate Buy$390.0044.36% UpsideCurrent Analyst Ratings BreakdownLatest ONC, TLM, EVG, and FUM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026ONCBeOne Medicines Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/2/2026ONCBeOne Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$425.00 ➝ $436.005/15/2026ONCBeOne Medicines Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$364.00 ➝ $367.005/7/2026ONCBeOne Medicines Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$395.005/7/2026ONCBeOne Medicines GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$410.00 ➝ $420.005/7/2026ONCBeOne Medicines BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$405.00 ➝ $409.005/7/2026ONCBeOne Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$423.00 ➝ $425.005/7/2026ONCBeOne Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$411.00 ➝ $413.005/4/2026ONCBeOne Medicines Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$400.005/4/2026ONCBeOne Medicines Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVGEaton Vance Short Duration Diversified Income Fund$15.46MN/AN/AN/AN/AN/AONCBeOne Medicines$5.34B5.55$4.02 per share67.21$39.77 per share6.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVGEaton Vance Short Duration Diversified Income FundN/AN/AN/AN/AN/AN/AN/AN/AN/AONCBeOne Medicines$286.93M$4.4760.4425.58N/A8.94%12.06%6.69%N/ALatest ONC, TLM, EVG, and FUM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2026Q1 2026ONCBeOne MedicinesN/A$0.25N/A$1.95N/A$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEVGEaton Vance Short Duration Diversified Income Fund$0.968.90%N/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ALatest ONC, TLM, EVG, and FUM DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/1/2026EVGEaton Vance Short Duration Diversified Income Fundmonthly$0.07398.32%6/15/20266/15/20266/30/20265/1/2026EVGEaton Vance Short Duration Diversified Income Fundmonthly$0.07408.3%5/15/20265/15/20265/29/20264/1/2026EVGEaton Vance Short Duration Diversified Income Fundmonthly$0.07348.16%4/15/20264/15/20264/30/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVGEaton Vance Short Duration Diversified Income FundN/AN/AN/AONCBeOne Medicines0.203.643.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVGEaton Vance Short Duration Diversified Income FundN/AONCBeOne Medicines48.55%Insider OwnershipCompanyInsider OwnershipEVGEaton Vance Short Duration Diversified Income FundN/AONCBeOne Medicines6.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVGEaton Vance Short Duration Diversified Income FundN/AN/AN/ANot OptionableONCBeOne Medicines12,000109.72 million102.93 millionN/AONC, TLM, EVG, and FUM HeadlinesRecent News About These CompaniesTemasek Holdings Private Ltd Sells 91,877 Shares of BeOne Medicines Ltd. - Sponsored ADR $ONCJune 16 at 8:18 AM | marketbeat.comTitus Ball Sells 169 Shares of BeOne Medicines (NASDAQ:ONC) StockJune 16 at 5:15 AM | insidertrades.comBeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 1,949 Shares of StockJune 16 at 4:34 AM | americanbankingnews.comBarclays Sticks to Its Buy Rating for BeOne Medicines (ONC)June 15, 2026 | theglobeandmail.comWolfe Research Sticks to Its Buy Rating for BeOne Medicines (ONC)June 13, 2026 | theglobeandmail.comBeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026June 13, 2026 | ncnewsonline.comNBeOne highlights phase 3 BRUKINSA data in older CLL patients and advances leadership position in BTK inhibitors (ONC)June 13, 2026 | msn.comJohn Oyler Sells 4,940 Shares of BeOne Medicines (NASDAQ:ONC) StockJune 12, 2026 | americanbankingnews.comBarings LLC Reduces Position in BeOne Medicines Ltd. - Sponsored ADR $ONCJune 12, 2026 | marketbeat.comBeOne Medicines (NASDAQ:ONC) Insider Sells $36,900.88 in StockJune 11, 2026 | insidertrades.comBeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA BenefitJune 11, 2026 | businesswire.comCapital International Sarl Raises Holdings in BeOne Medicines Ltd. - Sponsored ADR $ONCJune 7, 2026 | marketbeat.comBeOne Medicines Ltd. - Sponsored ADR $ONC Position Raised by Capital International InvestorsJune 7, 2026 | marketbeat.comBeOne Medicines Ltd. - Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock?June 5, 2026 | zacks.comBeOne Medicines (ONC) Valuation Check After ASCO 2026 Solid Tumor UpdatesJune 5, 2026 | finance.yahoo.comBeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO - SlideshowJune 3, 2026 | seekingalpha.comBeOne Medicines Ltd. - Sponsored ADR $ONC Shares Purchased by BNP Paribas Financial MarketsJune 3, 2026 | marketbeat.comBeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO TranscriptJune 2, 2026 | seekingalpha.comBeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3June 2, 2026 | marketbeat.comSummit rises after lung cancer drug trial shows 15% higher survival rate than rival'sJune 1, 2026 | reuters.comBeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026May 29, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesEverpure: AI Storage Uncertainty Overshadows Breakneck GrowthBy Leo Miller | June 10, 2026CAVA Group’s Stock Looks Delicious After Strong EarningsBy Chris Markoch | May 22, 2026AST SpaceMobile’s SpaceX Catalyst Could Come With a Volatility WarningBy Jessica Mitacek | June 10, 2026Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?By Sam Quirke | June 6, 2026If the Market Rally Stalls, This ETF Can Insulate PortfoliosBy Jessica Mitacek | May 28, 2026ONC, TLM, EVG, and FUM Company DescriptionsEaton Vance Short Duration Diversified Income Fund NYSE:EVG$10.78 +0.12 (+1.08%) Closing price 06/18/2026 03:57 PM EasternExtended Trading$10.78 0.00 (0.00%) As of 06/18/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eaton Vance Short Duration Diversified Income Fund is a closed ended fixed income mutual fund launched and managed by Eaton Vance Management. The fund invests in fixed income markets of the United States. It primarily invests in senior, secured floating-rate loans, bank deposits denominated in foreign currencies, debt obligations of foreign governmental and corporate issuers, and mortgage-backed securities. The fund invests in fixed income securities operating across diversified sectors. It invests in fixed income securities with an average duration of 1.76 years and an average credit quality of least BBB. The fund benchmarks the performance of its portfolio against the S&P/LSTA Leveraged Loan Index. It was formerly known as Eaton Vance Low Duration Diversified Income Fund. Eaton Vance Short Duration Diversified Income Fund was formed on February 28, 2005 and is domiciled in the United States.BeOne Medicines NASDAQ:ONC$270.15 +7.47 (+2.84%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$270.56 +0.41 (+0.15%) As of 06/18/2026 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
